Cargando…
Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?
Over the last 6 years, the treatment of metastatic renal cell carcinoma (mRCC) has undergone dramatic changes. A better understanding of the pathogenesis and tumor biology of sporadic renal cell carcinoma has led to the approval of 6 drug regimens: 3 oral multi-targeted tyrosine-kinase inhibitors (s...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235998/ https://www.ncbi.nlm.nih.gov/pubmed/22174596 http://dx.doi.org/10.4137/CMO.S6087 |